Treatment choice of immunotherapy or further chemotherapy for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis

Pediatric Blood and Cancer

Volumn 59, Issue 2, 2012, Pages 265-270

  Shiraishi, Akira ^a   Ohga, Shouichi ^a   Doi, Takehiko ^a   Ishimura, Masataka ^a   Takimoto, Tomohito ^a   Takada, Hidetoshi ^a   Miyamoto, Toshihiro ^a   Abe, Yasunobu ^a   Hara, Toshiro ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Epstein Barr virus associated hemophagocytic lymphohistiocytosis; Etoposide; Familial hemophagocytic lymphohistiocytosis; Hematopoietic stem cell transplantation; Immunochemotherapy

Indexed keywords

C REACTIVE PROTEIN; CYCLOSPORIN A; ETOPOSIDE; FERRITIN; HEMOGLOBIN; IMMUNOGLOBULIN; INTERLEUKIN 2 RECEPTOR ALPHA; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; PREDNISOLONE; VIRUS DNA;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BLOOD CELL COUNT; BLOOD CLOTTING DISORDER; CANCER REGRESSION; CD25+ T LYMPHOCYTE; CELL SELECTION; CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; DISEASE COURSE; DISEASE DURATION; EPSTEIN BARR VIRUS; FEMALE; FERRITIN BLOOD LEVEL; FEVER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBIN BLOOD LEVEL; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HEPATOSPLENOMEGALY; HIGH RISK PATIENT; HUMAN; IMMUNOTHERAPY; INFANT; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; NEUTROPHIL COUNT; NONHUMAN; ONSET AGE; PRESCHOOL CHILD; PRIMARY INFECTION; PRIORITY JOURNAL; PROGNOSIS; REMISSION; RETROSPECTIVE STUDY; SCHOOL CHILD; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THROMBOCYTE COUNT; TREATMENT RESPONSE; VIRUS LOAD;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHILD; CHILD, PRESCHOOL; EPSTEIN-BARR VIRUS INFECTIONS; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOTHERAPY; INFANT; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MALE; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862262324     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24039     Document Type: Article

References (40)

1. Odumade OA, Hogquist KA, Balfour HH, Jr. Progress and problems in understanding and managing primary Epstein-Barr virus infections. Clin Microbiol Rev 2011; 24: 193-209.
2. Ohga S, Nomura A, Takada H, et al. Epstein-Barr virus associated diseases in childhood. Immunological aspects of Epstein-Barr virus infection. Crit Rev Oncol Hematol 2002; 44: 203-215.
3. Risdall RJ, McKenna RW, Nesbit ME, et al. Virus-associated hemophagocytic syndrome: A benign histiocytic proliferation distinct from malignant histiocytosis. Cancer 1979; 44: 993-1002.
4. Cetica V, Pende D, Griffiths GM, et al. Molecular basis of familial hemophagocytic lymphohistiocytosis. Haematologica 2010; 95: 538-541.
5. + T cells and interferon gamma are essential for the disorder. Blood 2004; 104: 735-743.
6. Chuang HC, Lay JD, Chuang SE, et al. Epstein-Barr virus (EBV) latent membrane protein-1 down-regulates tumor necrosis factor-alpha (TNF-alpha) receptor-1 and confers resistance to TNF-alpha-induced apoptosis in T cells: Implication for the progression to T-cell lymphoma in EBV-associated hemophagocytic syndrome. Am J Pathol 2007; 170: 1607-1617.
7. Toga A, Wada T, Sakakibara Y, et al. Clinical significance of cloned expansion and CD5 down-regulation in Epstein-Barr virus (EBV)-infected CD8+ T lymphocytes in EBV-associated hemophagocytic lymphohistiocytosis. J Infect Dis 2010; 201: 1923-1932.
8. Kasahara Y, Yachie A, Takei K, et al. Differential cellular targets of Epstein-Barr virus (EBV) infection between acute EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Blood 2001; 98: 1882-1888.
9. Ohga S, Nomura A, Takada H, et al. Epstein-Barr virus (EBV) load and cytokine gene expression in activated T cells of chronic active EBV infection. J Infect Dis 2001; 183: 1-7.
10. Cohen JI, Kimura H, Nakamura S, et al. Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: A status report and summary of an international meeting, 8-9 September 2008. Ann Oncol 2009; 20: 1472-1482.
11. Sato E, Ohga S, Kuroda H, et al. Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan. Am J Hematol 2008; 83: 721-727.
12. Imashuku S, Teramura T, Tauchi H, et al. Longitudinal follow-up of patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Haematologica 2004; 89: 183-188.
13. Ohga S, Kudo K, Ishii E, et al. Hematopoietic stem cell transplantation for familial hemophagocytic lymphohistiocytosis and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Japan. Pediatr Blood Cancer 2010; 54: 299-306.
14. Sonke GS, Ludwig I, van Oosten H, et al. Poor outcomes of chronic active Epstein-Barr virus infection and hemophagocytic lymphohistiocytosis in non-Japanese adult patients. Clin Infect Dis 2008; 47: 105-108.
15. Beutel K, Gross-Wieltsch U, Wiesel T, et al. Infection of T lymphocytes in Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children of non-Asian origin. Pediatr Blood Cancer 2009; 53: 184-190.
16. Fox CP, Shannon-Lowe C, Gothard P, et al. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults characterized by high viral genome load within circulating natural killer cells. Clin Infect Dis 2010; 51: 66-69.
17. Elazary AS, Wolf DG, Amir G, et al. Severe Epstein-Barr virus-associated hemophagocytic syndrome in six adult patients. J Clin Virol 2007; 40: 156-159.
18. Ahn JS, Rew SY, Shin MG, et al. Clinical significance of clonality and Epstein-Barr virus infection in adult patients with hemophagocytic lymphohistiocytosis. Am J Hematol 2010; 85: 719-722.
19. Belyea B, Hinson A, Moran C, et al. Spontaneous resolution of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2010; 55: 754-756.
20. RamaChandran S, Ariffin H. Secondary acute myeloid leukemia after etoposide therapy for haemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2009; 53: 488-490.
21. Henter JI, Horne A, Aricó M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007; 48: 124-131.
22. Okano M, Kawa K, Kimura H, et al. Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection. Am J Hematol 2005; 80: 64-69.
23. Sumaya CV, Ench Y. Epstein-Barr virus infectious mononucleosis in children. I. Clinical and general laboratory findings. Pediatrics 1985; 75: 1003-1010.
24. Ohga S, Ishimura M, Yoshimoto G, et al. Clonal origin of Epstein-Barr virus (EBV)-infected T/NK-cell subpopulations in EBV-positive T/NK cell lymphoproliferative disorders of childhood. J Clin Virol 2011; 74: 449-458.
25. Fischer A, Virelizier JL, Arenzana-Seisdedos F, et al. Treatment of four patients with erythrophagocytic lymphohistiocytosis by a combination of epipodophyllotoxin, steroids, intrathecal methotrexate, and cranial irradiation. Pediatrics 1985; 76: 263-268.
26. Henter JI, Samuelsson-Horne AC, Arico M, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplant. Blood 2002; 100: 2367-2373.
27. Toubo T, Suga N, Ohga S, et al. Successful unrelated cord blood transplantation for Epstein-Barr virus-associated lymphoproliferative disease with hemophagocytic syndrome. Int J Hematol 2004; 80: 458-462.
28. Imashuku S, Hibi S, Ohara T, et al. Effective control of Epstein-Barr virus-related hemophagocyctic lymphohistiocytosis with immunochemotherapy. Blood 1999; 93: 1869-1874.
29. Imashuku S, Kuriyama K, Teramura T, et al. Requirement for etoposide in the treatment of Epstein-Barr Virus-associated hemophagocytic lymphohistiocytosis. J Clin Oncol 2001; 19: 2665-2673.
30. Ohga S, Matsuzaki A, Nishizaki M, et al. Inflammatory cytokines in virus-associated hemophagocytic syndrome. Interferon-gamma as a sensitive indicator of disease activity. Am J Pediatr Hematol Oncol 1993; 15: 291-298.
31. Ishii E, Ohga S, Imashuku S, et al. Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol 2007; 86: 58-65.
32. Teramura T, Tabata Y, Yagi T, et al. Quantitative analysis of cell-free Epstein-Barr virus genome copy number in patients with EBV-associated hemophagocytic lymphohistiocytosis. Leuk Lymphoma 2002; 43: 173-179.
33. Dohno S, Maeda A, Ishiura Y, et al. Diagnosis of infectious mononucleosis caused by Epstein-Barr virus in infants. Pediatr Int 2010; 52: 536-540.
34. Arai A, Imadome K, Watanabe Y, et al. Clinical features of adult-onset chronic active Epstein-Barr virus infection: A retrospective analysis. Int J Hematol 2011; 93: 602-609.
35. Ohga S, Nomura A, Takada H, et al. Dominant expression of interleukin-10 and transforming growth factor-β genes in activated T-cells of chronic active Epstein-Barr virus infection. J Med Virol 2004; 74: 449-458.
36. Rowe M, Zuo J. Immune responses to Epstein-Barr virus: Molecular interactions in the virus evasion of CD8+ T cell immunity. Microbes Infect 2010; 12: 173-181.
37. Takada H, Ohga S, Mizuno Y, et al. Oversecretion of IL-18 in haemophagocytic lymphohistiocytosis: A novel marker of disease activity. Br J Haematol 1999; 106: 182-189.
38. Gotoh K, Ito Y, Shibata-Watanabe Y, et al. Clinical and virological characteristics of 15 patients with chronic active Epstein-Barr virus infection treated with hematopoietic stem cell transplantation. Clin Infect Dis 2008; 46: 1525-1534.
39. Kawa K, Sawada A, Sato M, et al. Excellent outcome of allogeneic hematopoietic SCT with reduced-intensity conditioning for the treatment of chronic active EBV infection. Bone Marrow Transplant 2011; 46: 77-83.
40. Cohen JI, Jaffe ES, Dale JK, et al. Characterization and treatment of chronic active Epstein-Barr virus disease: A 28-year experience in the United States. Blood 2011; 117: 5835-5849.